A Novel Classification of Lung Cancer into Molecular Subtypes

MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance

(2012) Rajani Kanteti et al.   JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY

Mind-mapping for lung cancer: Towards a personalized therapeutics approach

(2011) N. Mollberg et al.   ADVANCES IN THERAPY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein Kinase (MAPK) and Phosphatidylinositol-3-kinase (PI3K)/AKT pathways

(2011) Jun-ichi Hanai et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

(2011) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

(2011) Vienna Ludovini et al.   Journal of Thoracic Oncology

A Melanoma Molecular Disease Model

(2011) Smruti J. Vidwans et al.   PLoS One

Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung Adenocarcinomas

(2011) Putty-Reddy Sudhir et al.   PLoS One

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Personalized Treatment of Lung Cancer

(2011) Ravi Salgia et al.   SEMINARS IN ONCOLOGY

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

(2011) Martin Sattler et al.   Therapeutic Advances in Medical Oncology

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas

(2010) Nancy Van Damme et al.   BMC CANCER

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

(2010) C. H. Chung et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

(2010) Giuseppe Bronte et al.   CANCER TREATMENT REVIEWS

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

(2010) Geoffrey R. Oxnard et al.   CLINICAL CANCER RESEARCH

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Pathway as a Therapeutic Target

(2010) Eric S. Kim et al.   Journal of Thoracic Oncology

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503

(2010) Joseph M. Amann et al.   Journal of Thoracic Oncology

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

(2010) Xia Pu et al.   LUNG CANCER

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

(2010) Xuchao Zhang et al.   Molecular Cancer

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

(2010) Filip Janku et al.   Nature Reviews Clinical Oncology

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases

(2010) Yi-Hung Carol Tan et al.   PLoS One

MET molecular mechanisms and therapies in lung cancer

(2010) Ryan E. Lawrence et al.   Cell Adhesion & Migration

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

(2009) Tsuyoshi Takahashi et al.   ANNALS OF SURGICAL ONCOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

(2009) S. Krishnaswamy et al.   CLINICAL CANCER RESEARCH

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

The Rationale and Development of Therapeutic Insulin-like Growth Factor Axis Inhibition for Lung and Other Cancers

(2009) D. Ross Camidge et al.   Clinical Lung Cancer

Reovirus-based therapy for cancer

(2009) Kevin Kelly et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Isoform-specific ras functions in development and cancer

(2009) Margaret P Quinlan et al.   Future Oncology

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

(2009) Takamitsu Onitsuka et al.   LUNG CANCER

VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

(2009) David P. Carbone et al.   LUNG CANCER

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers

(2009) Guang Jin et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

(2008) S. A. Eccles et al.   CANCER RESEARCH

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA